- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Adaptive Pharmacotherapy Shows Promise in Smoking Cessation: JAMA
A recent study published in the Journal of American Medical Association found that adaptive pharmacotherapy, a method of tailoring medication regimens based on patient response, significantly improves smoking cessation rates in a clinical practice setting. The study, stopped early due to the COVID-19 pandemic, compared adaptive treatment with standard treatment for smoking cessation.
Unlike traditional approaches that provide a fixed medication regimen, adaptive treatment allows for adjustments based on the patient's response to the treatment. While previous studies have shown the efficacy of adaptive treatment using precessation nicotine patches, the use of precessation varenicline (a medication to help quit smoking) and its application in clinical practice settings remained largely unexplored.
The primary objective of this double-blinded, stratified placebo-controlled randomized clinical trial was to determine whether adaptive pharmacotherapy could achieve higher smoking abstinence rates compared to standard pharmacotherapy in a real-world clinical practice setting.
Participants in the trial were given the choice between varenicline or nicotine patches, and they were then randomized into either the adaptive or nonadaptive (standard) treatment group. The adaptive group began their chosen medication four weeks before their target quit day. After two weeks, participants were assessed for their response to the treatment.
Nonresponders in the adaptive group, those who didn't reduce their daily cigarette consumption by at least 50%, received additional medication (bupropion) alongside their chosen treatment. Responders in the adaptive group and participants in the standard group received placebo treatment.
The main outcome measure was biochemically verified 30-day continuous smoking abstinence 12 weeks after their target quit smoking day. The trial enrolled 188 participants, with an average age of 49.1 years, of which 54% were female.
The results were promising, showing that adaptive pharmacotherapy was significantly more effective than standard treatment. Biochemically verified 30-day continuous smoking abstinence was observed in 24% of participants in the adaptive treatment group compared to only 9% in the standard treatment group.
Among participants who used varenicline, the adaptive treatment group showed a 28% abstinence rate compared to 8% in the standard treatment group.
However, it's worth noting that sleep problems were more common in the varenicline adaptive treatment group than in the varenicline standard treatment group.
Reference:
Davis, J. M., Masclans, L., & Rose, J. E. (2023). Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch. In JAMA Network Open (Vol. 6, Issue 9, p. e2332214). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2023.32214
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751